Dr. Lawrence Friedman and Mr. Jerry Sachs will become Board Directors while Dr. Stephen Heyse will leave the Board in order to rejoin the Biomedical Advanced Research and Development Authority in support of its COVID-19 Medical Countermeasures Portfolio
Bethesda, MD – The Board of the Medical Technology and Practice Patterns Institute (MTPPI) is pleased to announce that Dr. Lawrence Friedman and Mr. Jerry Sachs have agreed to join the Institute’s Board of Directors.
Dr. Friedman is an internationally recognized expert on clinical trials methodology and co-authored Fundamentals of Clinical Trials, which is now in its fifth edition. After receiving his Doctor of Medicine degree from the University of Pittsburgh and training in internal medicine, Dr. Friedman was recruited to the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health where he served as the Director of the Division of Epidemiology and Clinical Applications and the Assistant Director for Ethics and Clinical Research. During his over 30 years of working at the NHLBI, Dr. Friedman was involved in numerous clinical trials and epidemiology studies, playing major roles in trial design, management, and monitoring. In addition to his work at the NHLBI, Dr. Friedman served as a trials-consultant to other NIH institutes as well as governmental and nongovernmental organizations. Dr. Friedman has been named to many data and safety monitoring committees and has served as an editor of Data Monitoring in Clinical Trials – a Case Studies Approach. He has also been a past president of the Society for Clinical Trials.
Mr. Jerry Sachs comes to the MTPPI Board with a deep expertise in consumer marketing and operational execution gained over an extensive career that saw him serve in several industries. Mr. Sachs graduated from Case Western Reserve University and joined the Baltimore Orioles baseball organization, rising to the position of public relations director. He then joined the Atlanta Braves as the team’s public relations director. While in Atlanta, Mr. Sachs was recruited by the Coca-Cola Company to become its first director of sports marketing. The professional sports industry called him back to Baltimore in the 70s when he became the Vice President and General Manager of the Baltimore Bullets. In this role, he oversaw the design of the Capital Centre and eventually became President of the Centre Group, the operating entity that included the Washington Bullets, the Washington Capitals, Centre Management and the DC area Ticketmaster franchise. While he was with the Bullets, they went to the NBA finals four times and won the championship in 1978. He ended his career spending 10 years as Assistant to the Director the Smithsonian’s National Museum of Natural History; subsequently serving on several Boards, including the NIH’s Patient Advisory Group and Friends of Patients at the NIH. He is a long-term patient of the NIH. Mr. Sachs is a veteran of the US Marine Corps.
“MTPPI is honored to have both Dr. Friedman and Mr. Sachs join its Board of Directors. As the world continues to grapple with the COVID-19 pandemic, we have seen how important it is for the healthcare system to conduct both rigorous scientific research and engaging patient education to mitigate the effects of the virus,” said Dennis Cotter, President of MTPPI. “The Institute’s mission is to translate the results of its research into patient-centered tools that can be used to improve outcomes. Dr. Friedman and Mr. Sachs have the expertise to further guide us in the pursuit of these goals and we look forward to working with them.”
“Additionally, I want to thank Dr. Stephen Heyse for his dedicated service to MTPPI’s Board and its research. We wish him well as he helps the Biomedical Advanced Research and Development Authority develop its COVID-19 portfolio at this critical juncture,” said Mr. Cotter.
For media inquiries, please contact email@example.com